1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow imdevimab: new trials by email Literature Review of imdevimab trials Research Report on imdevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease REGN14256, imdevimab, casirivimab + imdevimab - SARS-CoV-2 | Phase 1 / Phase 2 | Terminated | Regeneron Pharmaceuticals | 25 | 2021-11-08 | 2025-10-28 |
COVID-19 (1) · Coronavirus Infections (1)
United States (1)